My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 291

    1.

    The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.

    [No authors listed]

    Diabetes Care. 1999 Apr;22(4):623-34. Erratum in: Diabetes Care 1999 Aug;22(8):1389. PMID: 10189543 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations]

    Flórez H.

    Invest Clin. 1997 Mar;38(1):39-52. Review. Spanish. PMID: 9235072 [PubMed - indexed for MEDLINE]Related articles

    3.

    [Progress in the prevention of type 2 diabetes]

    Schernthaner G.

    Wien Klin Wochenschr. 2003 Nov 28;115(21-22):745-57. Review. German. PMID: 14743578 [PubMed - indexed for MEDLINE]Related articles

    4.

    TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.

    Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA.

    Control Clin Trials. 1998 Apr;19(2):217-31.PMID: 9551285 [PubMed - indexed for MEDLINE]Related articles

    5.

    The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.

    Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S; Diabetes Prevention Program Research Group.

    Ann Intern Med. 2005 Apr 19;142(8):611-9.PMID: 15838067 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.

    Freemark M, Bursey D.

    Pediatrics. 2001 Apr;107(4):E55.PMID: 11335776 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program.

    Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE; Diabetes Prevention Program Research Group.

    Diabetes. 2005 Apr;54(4):1150-6.PMID: 15793255 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group.

    N Engl J Med. 2002 Feb 7;346(6):393-403.PMID: 11832527 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

    Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

    Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947. PMID: 11874944 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial.

    Zinman B, Harris SB, Gerstein HC, Young TK, Raboud JM, Neuman J, Hanley AJ.

    Diabetes Obes Metab. 2006 Sep;8(5):531-7.PMID: 16918588 [PubMed - indexed for MEDLINE]Related articles

    11.

    Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.

    Berkowitz K, Peters R, Kjos SL, Goico J, Marroquin A, Dunn ME, Xiang A, Azen S, Buchanan TA.

    Diabetes. 1996 Nov;45(11):1572-9.PMID: 8866563 [PubMed - indexed for MEDLINE]Related articles

    12.

    Background and recruitment data for the U.S. Diabetes Prevention Program.

    Fujimoto WY; Diabetes Prevention Program Research Group.

    Diabetes Care. 2000 Apr;23 Suppl 2:B11-3. Erratum in: Diabetes Care 2000 Jun;23(6):876. PMID: 10860185 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.

    Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP.

    Diabetes. 2002 Sep;51(9):2796-803.PMID: 12196473 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.

    Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL.

    Ann Intern Med. 2001 May 1;134(9 Pt 1):737-45.PMID: 11329231 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.

    Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, Andres R, Saudek C, Edelstein SL, Arakaki R, Murphy MB, Shamoon H; Diabetes Prevention Program Research Group.

    Diabetes. 2005 Aug;54(8):2404-14.PMID: 16046308 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.

    Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, Fowler S, Kahn SE; Diabetes Prevention Program Research Group.

    J Clin Endocrinol Metab. 2008 Dec;93(12):4774-9. Epub 2008 Sep 30.PMID: 18826999 [PubMed - indexed for MEDLINE]Related articles

    17.

    Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.

    Eddy DM, Schlessinger L, Kahn R.

    Ann Intern Med. 2005 Aug 16;143(4):251-64.PMID: 16103469 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Alcohol consumption and diabetes risk in the Diabetes Prevention Program.

    Crandall JP, Polsky S, Howard AA, Perreault L, Bray GA, Barrett-Connor E, Brown-Friday J, Whittington T, Foo S, Ma Y, Edelstein SL; Diabetes Prevention Program Research Group.

    Am J Clin Nutr. 2009 Sep;90(3):595-601. Epub 2009 Jul 29.PMID: 19640960 [PubMed - indexed for MEDLINE]Related articles

    19.

    Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.

    Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, Foot E, Seghieri G, Ferrannini E.

    Clin Pharmacol Ther. 1997 Aug;62(2):194-202.PMID: 9284856 [PubMed - indexed for MEDLINE]Related articles

    20.

    Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

    Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM.

    Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. Review.PMID: 15147610 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity